Mosaic ImmunoEngineering Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
| ITEM 11. | EXECUTIVE COMPENSATION |
|---|
The following table summarizes the compensation of the named executive officers for the years ended December 31, 2025 and 2024.
| Name and Principal Position · Year · Salary ($) · Bonus ($) · Stock Awards ($) · Total Compensation ($) | ||||||
|---|---|---|---|---|---|---|
| Steven King, President, | 2025 | $250,000 | (1)(2)(6) | $– | $– | $250,000 |
| Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) | 2024 | $250,000 | (1)(2) | $– | $– | $262,147 |
| Paul Lytle, EVP, | 2025 | $12.185 | (1)(3)(5) | $– | $– | $12,185 |
| Chief Financial Officer (“CFO”) | 2024 | $116,846 | (1) (3)(4) | $– | $– | $136,371 |
| (1) | Of such amount, Mr. King and Mr. Lytle have agreed to defer 85% of their base salary payable in cash until such a time that the Company is able to raise at least $4 million in funding. |
| (2) | Of the 15% to be paid in cash, $54,808 and $17,308 has been accrued and not paid as of December 31, 2025 and 2024, respectively. |
| (3) | Of the 15% to be paid in cash, $21,047 and $8,862 has been accrued and not paid as of December 31, 2025 and 2024, respectively. |
| (4) | Effective June 1, 2024, Mr. Lytle reduced his time commitment to the Company to part-time status to provide no more than eight (8) hours of service per month. |
| (5) | Effective August 15, 2025, Mr. Lytle resigned as EVP, CFO of the Company and his Board position. |
| (6) | Effective August 15, 2025, Mr. King assumed the role of Chief Financial Officer and Principal Financial Officer. |
Outstanding Equity Awards
The following table sets forth certain information regarding unexercised stock options and unvested stock awards held by our named executive officer as of December 31, 2025:
| Option Awards · Stock Awards | |||||||
|---|---|---|---|---|---|---|---|
| Name | Grant Date | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable(1) | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($)(3) |
| Steven King | 12/16/2020(1) | – | – | – | – | 65,218 | 20,283 |
| 12/16/2020(2) | – | – | – | – | 43,479 | 13,522 | |
| (1) | RSU award will vest 100% on the sooner of (i) August 31, 2026, provided the Company is listed on a national exchange such as the Nasdaq Stock Market prior to August 31, 2026 (ii) upon a merger or acquisition of the Company, provided the holder agrees to accept the underlying shares in writing, or (iii) upon the holders last date of employment, provided the holder agrees to accept the underlying shares in writing. |
| (2) | RSU award will vest 100% on the sooner of (i) August 31, 2027, provided the Company is listed on a national exchange such as the Nasdaq Stock Market prior to August 31, 2027 (ii) upon a merger or acquisition of the Company, provided the holder agrees to accept the underlying shares in writing, or (iii) upon the holders last date of employment, provided the holder agrees to accept the underlying shares in writing. |
| (3) | Market value is calculated based on the closing price of our common stock of $0.311 per share on December 31, 2025, times the number of shares subject to the RSU award. Each RSU represents the contingent right to receive, upon vesting, one share of our common stock. |
We donot grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.